Top Tweets for #BioSimilar
Samsung Bioepis and Teva strike global deal six biosimilars
https://t.co/mzrIiRONAh
#SamsungBioepis #TevaPharmaceuticalsIndustries #biosimilar
@indpharmapost
On Sept 25, 2026, the FDA approved Degevma (denosumab-adet), a biosimilar to Xgeva (denosumab), making it the most recently approved U.S. biosimilar. #Degevma #Xgeva #biosimilar https://t.co/gFE8qaDHmj
#Fresenius takes full ownership of #mAbxience #biosimilars platform. The acquisition gives the therapy-focused healthcare company full control of mAbxience's manufacturing network and future capacity investments. https://t.co/wQrCPt7IOh #biosimilar #FreseniusKabi #biopharma
🔄 El switch a un #biosimilar, ¿qué impacto tiene en pacientes con #enfermedad #inflamatoria #intestinal?
📊Un estudio en Alemania entre 2014 y 2022 evaluó a 3.464 pacientes con EII tratados con #infliximab o #adalimumab, de los cuales 914 cambiaron a un biosimilar.
Los resultados mostraron👇
💉 que no hubo cambios en la #salud asociados al switch y los pacientes que cambiaron a un #biosimilar presentaron una mayor #persistencia del #tratamiento.
💵 una reducción de los #costes al disminuir #gasto #farmacéutico, con reducciones significativas durante los primeros dos años.
https://t.co/2j6dNwKKdl
.@WaltzHealth, @FreseniusKabi partner for direct-to-payer #biosimilar program https://t.co/wfyISm43Ia
Developing biosimilars of medicines that are due to come off patent could save @NHSuk up to £40m per year on average, a @Medicines_UK report has said
#ukpharmacy #biosimilar #drugdevelopment
https://t.co/0MtENpveWO
Build a clearer case for #biosimilar approval. See how #QPS integrates analytical similarity, PK and immunogenicity data to reduce uncertainty, anticipate regulatory questions and keep your program moving. Download the white paper: https://t.co/RybvDuPYyA or email [email protected].
#Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing #biosimilar medicines. #Fresenius https://t.co/OoJV1fKpYJ
"The Association for Accessible Medicines [a trade group representing #generic drugmakers]said brand-name drugmakers [offer] PBMs massive rebates on high-price original drugs. Drugmakers can use that leverage to discourage coverage of cheaper #biosimilar competitors."🤔
#Sandoz targets 100-plus #biosimilars in portfolio by 2040, up from 13. The company will invest about $300 million in a new #drugsubstance facility in #Slovenia to expand its #biosimilar #manufacturing capacity. https://t.co/X49kRgDmOx #sterileinjectables #fillfinish #biologics
@EpygenBiotech On the 15th foundation day of Epygen India, I congratulate the team for achieving this milestone of excellence through innovation and perseverance in critical biopharmaceutical segments of Cardiovascular, Anti-diabetic and Protein-Vaccines. #Biopharma, #Biosimilar
Dr Reddy’s wins marketing approval for Abatacept biosimilar in India
#Abatacept I #Biosimilar I #Approval I #India I #arthritis I #Inflammation I @drreddys
Read more:
https://t.co/g0lh5RsdRL
How Is Enoxaparin Sodium API & Injection Scientifically Characterised for Global Quality, Biological Potency and Regulatory Compliance?
https://t.co/LHbGOOMpog
#EnoxaparinSodiumAPI #EnoxaparinSodiumInjection #Bioassay #Biosimilar #testing #Idma #Idmalaboratoriess #analysis
Our Sept 2026 issue is live!
Including research on #BMI and JAK inhibtors,
predicting #psoriaticarthritis, rheumatic disease diagnoses pre and post #COVID19, and a #secukinumab #biosimilar, plus much more! https://t.co/XGoKvOAJDo
Cover by @emmacreats
Bharat Parenterals doubles Savli facility capex to Rs. 300 crore as it targets global biologics CDMO market
https://t.co/VQ03YAyk9E
#BharatParenteralsLtd #VarenyamBiolifesciences #biologics #biosimilar #CDMO
@indpharmapost
#Biocon expects stronger second half on new #biosimilar launches
@ekta_batra
https://t.co/OBYIkuYPwp
Treatment guidelines for Rheumatoid Arthritis are changing because #biosimilar drugs are becoming cheaper and more widely available, making advanced treatments financially feasible earlier in the treatment process. https://t.co/U6hZ10ulXn
Lupin announced that the U.S. FDA has approved its ranibizumab, RanluspecTM (ranibizumab-hkdz), as an interchangeable biosimilar referencing to Lucentis® (Genentech). Read More: https://t.co/jV8mia1n9F
#Lupin #USFDA #Biosimilar #RegulatoryApproval #HealthcareInnovation
FDA approves Immgolis and Immgolis Intri (golimumab-sldi) as an interchangeable #biosimilar to Simponi and Simponi Aria (golimumab). https://t.co/zKJQ7cYInO
This is the first approval of an interchangeable biosimilar to golimumab.
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.3M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers